AR040279A2 - Composiciones que contiene sal de sertralina - Google Patents

Composiciones que contiene sal de sertralina

Info

Publication number
AR040279A2
AR040279A2 ARP030102179A ARP030102179A AR040279A2 AR 040279 A2 AR040279 A2 AR 040279A2 AR P030102179 A ARP030102179 A AR P030102179A AR P030102179 A ARP030102179 A AR P030102179A AR 040279 A2 AR040279 A2 AR 040279A2
Authority
AR
Argentina
Prior art keywords
compositions containing
sertraline salt
containing sertraline
cmax
solubilizing agent
Prior art date
Application number
ARP030102179A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21971159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR040279(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR040279A2 publication Critical patent/AR040279A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Composición que contiene una forma de sal de sertralina altamente soluble que tiene una solubilidad mayor a 10mg/ml en agua pura y una cantidad de agente solublilizante suficiente para producir in vivo una Cmax y/o una AUC que es mayor en al menos un 10 % que la Cmax y/o la AUC producida por una composición comparativa de materia idéntica a la anterior pero sin incluir el mencionado agente solubilizante.
ARP030102179A 1997-07-01 2003-06-19 Composiciones que contiene sal de sertralina AR040279A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5141397P 1997-07-01 1997-07-01

Publications (1)

Publication Number Publication Date
AR040279A2 true AR040279A2 (es) 2005-03-23

Family

ID=21971159

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP980103146A AR015917A1 (es) 1997-07-01 1998-06-29 Composiciones de materia que contiene sertralina y procedimiento para aumentar su solubilidad en un medio acuoso
ARP030102179A AR040279A2 (es) 1997-07-01 2003-06-19 Composiciones que contiene sal de sertralina
ARP030102180A AR040280A2 (es) 1997-07-01 2003-06-19 Procedimiento para aumentar su solubilidad en un medio acuoso

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP980103146A AR015917A1 (es) 1997-07-01 1998-06-29 Composiciones de materia que contiene sertralina y procedimiento para aumentar su solubilidad en un medio acuoso

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP030102180A AR040280A2 (es) 1997-07-01 2003-06-19 Procedimiento para aumentar su solubilidad en un medio acuoso

Country Status (34)

Country Link
EP (1) EP0999829A1 (es)
JP (1) JP2000514100A (es)
KR (1) KR100366373B1 (es)
CN (1) CN1261794A (es)
AP (1) AP1192A (es)
AR (3) AR015917A1 (es)
AU (1) AU742535B2 (es)
BG (1) BG103918A (es)
BR (1) BR9810739A (es)
CA (1) CA2290974C (es)
CO (1) CO4940495A1 (es)
DZ (1) DZ2548A1 (es)
EA (1) EA002481B1 (es)
HN (1) HN1998000102A (es)
HR (1) HRP980377A2 (es)
HU (1) HUP0002236A3 (es)
ID (1) ID23429A (es)
IL (1) IL133076A (es)
IS (1) IS5260A (es)
MA (1) MA24587A1 (es)
NO (1) NO996520L (es)
OA (1) OA11243A (es)
PA (1) PA8454301A1 (es)
PE (1) PE97199A1 (es)
PL (1) PL337804A1 (es)
SK (1) SK181099A3 (es)
TN (1) TNSN98124A1 (es)
TR (1) TR199903297T2 (es)
TW (1) TW550087B (es)
UA (1) UA67741C2 (es)
UY (1) UY25071A1 (es)
WO (1) WO1999001120A1 (es)
YU (1) YU68299A (es)
ZA (1) ZA985708B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0016555A (pt) 1999-12-23 2002-09-17 Pfizer Prod Inc Composições farmacêuticas que proporcionam concentrações acrescidas de droga
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
MXPA03001771A (es) 2000-08-30 2003-06-04 Pfizer Prod Inc Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento.
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
CN101631593B (zh) * 2007-03-12 2014-08-13 帝斯曼知识产权资产管理有限公司 化妆品组合物
TH121482A (th) 2009-08-19 2013-02-28 นางสาวปัณณพัฒน์ เหลืองธาตุทอง องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน
WO2011081118A1 (ja) * 2009-12-29 2011-07-07 興和株式会社 経口投与用医薬組成物
KR20120123289A (ko) * 2009-12-29 2012-11-08 코와 가부시키가이샤 경구 투여용 고형 의약 조성물
CN109908354A (zh) * 2017-12-12 2019-06-21 万特制药(海南)有限公司 盐酸舍曲林口服浓缩液及其制备工艺
CN114894736B (zh) * 2022-05-20 2025-03-21 中化地质矿山总局地质研究院 一种氯化物型卤水中硝酸根的测定方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
ATE96999T1 (de) * 1989-08-30 1993-11-15 Pfizer Verwendung von sertralin zur behandlung von abhaengigkeiten von chemischen stoffen.
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
HRP980377A2 (en) 1999-04-30
IS5260A (is) 1999-11-19
EP0999829A1 (en) 2000-05-17
ZA985708B (en) 2000-01-10
BR9810739A (pt) 2000-09-12
AR040280A2 (es) 2005-03-23
EA199900962A1 (ru) 2000-08-28
DZ2548A1 (fr) 2003-02-08
PL337804A1 (en) 2000-09-11
OA11243A (en) 2003-07-24
HUP0002236A3 (en) 2003-12-29
NO996520L (no) 2000-02-29
KR100366373B1 (ko) 2003-01-14
HUP0002236A2 (hu) 2003-08-28
AR015917A1 (es) 2001-05-30
UA67741C2 (uk) 2004-07-15
YU68299A (sh) 2002-06-19
WO1999001120A1 (en) 1999-01-14
HN1998000102A (es) 1999-01-08
AP1192A (en) 2003-07-23
UY25071A1 (es) 2000-12-29
CA2290974A1 (en) 1999-01-14
TW550087B (en) 2003-09-01
TR199903297T2 (xx) 2000-07-21
SK181099A3 (en) 2000-07-11
PA8454301A1 (es) 2000-09-29
JP2000514100A (ja) 2000-10-24
BG103918A (en) 2000-07-31
ID23429A (id) 2000-04-20
AU7544898A (en) 1999-01-25
EA002481B1 (ru) 2002-06-27
CO4940495A1 (es) 2000-07-24
CN1261794A (zh) 2000-08-02
CA2290974C (en) 2004-04-27
AU742535B2 (en) 2002-01-03
IL133076A (en) 2003-12-10
TNSN98124A1 (fr) 2005-03-15
MA24587A1 (fr) 1998-12-31
IL133076A0 (en) 2001-03-19
NO996520D0 (no) 1999-12-28
PE97199A1 (es) 1999-10-05
AP9801280A0 (en) 1998-06-30
KR20010013365A (ko) 2001-02-26

Similar Documents

Publication Publication Date Title
BR9302738A (pt) Composicao oral substancialmente nao irritante,com sabor aceitavel
ES2167453T3 (es) Composicion de suministro medicamentoso que contiene quitosano o derivado del mismo con un potencial z. definido.
MX173433B (es) Composicion acuosa de ibuprofen y procedimiento para su preparacion
DE3874485D1 (de) Injizierbare, opazifizierende liposomzusammensetzung.
AR040279A2 (es) Composiciones que contiene sal de sertralina
UY23373A1 (es) Procedimiento para preparar nuevas composiciones analgesicas
ES2176684T3 (es) Nuevas asociaciones de principios activos que contienen clopidogrel y un antitrombotico.
ES2044156T3 (es) Jabon transparente que contiene un 1,2-alcanodiol.
ES2123721T3 (es) Formulaciones de rapamicina para inyecciones por via intravenosa.
PE68899A1 (es) Composicion que contiene paracetamol
MY105493A (en) Contrast media
MX9206150A (es) Agentes antiinflamatorios de derivados de tripeptidos
ES2103483T3 (es) Composiciones liquidas para limpieza que comprenden un sulfato de alquilo primario y tensioactivos no ionicos.
AR007852A1 (es) Una composicion de barra de jabon de base anionica que comprende tensioactivos anfoteros y/o zwitterionicos
PE33396A1 (es) Composicion para el tratamiento del ansia de nicotina y/o los sintomas de abstinencia de fumar
ES2187489T3 (es) Composiciones farmaceuticas a base de diclofenac.
ES2068240T3 (es) Composicion detergente.
MX169821B (es) Compociciones limpiadoras cremosas
ES2089613T3 (es) Composicion detergente.
GB9122674D0 (en) Toiletries composition
ES2186415T3 (es) Composiciones detergentes y para ablandar el agua.
ES2120234T3 (es) Agente blanqueador.
ES2144734T3 (es) Procedimiento para la obtencion de concentrados acuosos de tensioactivos.
BR9810996A (pt) Composição farmacêutica
ES2066578T3 (es) Composicion detergente liquida concentrada que contiene un agente secuestrante de tipo polifosfonato.

Legal Events

Date Code Title Description
FB Suspension of granting procedure